iBET has several established collaborations with national and international Pharma companies.
Over the last 20 years, iBET has been developing several projects for international pharmaceutical companies, such as Bayer, Novartis, Merck, Sanofi, Abbvie, Apceth, AstraZeneca, Glaxo-Smith-Kline, Merck & Co., among others.
R&D programs main areas include:
- process development for protein production (including Monoclonal Antibodies);
- production of virus-based vaccines; viral vectors for gene therapy (Retrovirus and Lentivirus, Adenovirus, Adeno Associated Virus and Baculovirus);
- development of tools and methodologies for cell therapy applications and pre-clinical research (novel 3D in vitro models for toxicology and disease models), namely the use of Stem Cells (hESC, Adult Stem Cells and iPS); and
- primary cultures of human hepatocytes, cancer and brain cells.
National Partners
Bial
Medinfar
Tecnimede
GenIbet Biopharmaceuticals
Lecifarma
International Partners
AbbVie, USA
Affilogic, France
Alloksys, The Netherlands
Apceth, Germany
Applied Sensor, Sweden
Aquaporin, Denmark
AstraZeneca, Sweden
Bayer, Germany
Boheringer Ingelheim, Germany
BioReliance, USA
Cellartis-Takara, Sweden
CEVEC, Germany
Crucell, The Netherlands
CSL Behring
Cytiva, Sweden
EMD Millipore, USA
Delta-Vir
Genethon, France
Georg-Speyer-Haus, Germany
Glaxo Smith Kline
Ingenasa, Spain
Janssen Biotech-Johnson & Johnson, USA
Janssen-Cilag GmbH International
Kemin
Lonza, UK
Merck Healthcare KGaA, Germany
Micromet-Amgen, Germany
Novasep, Belgium
Novartis, Switzerland
Novo Nordisk, Denmark
Pall Life Sciences, USA
PBS Biotech, USA
Pharmacelsus, Germany
Polymun, Austria
Redbiotec, Switzerland
Rubius Therapeutics
Sartorius-Stedim, Germany
Sanofi, France
Sumitomo Dainippon Pharma, Japan
TILT Biotherapeutics
Turnstone Biologics
Takeda
UNUM Therapeutics